# A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration

> **NCT00851409** · PHASE2 · COMPLETED · sponsor: **Pharming Technologies B.V.** · enrollment: 25 (actual)

## Conditions studied

- Genetic Disorders
- Hereditary Angioedema

## Interventions

- **DRUG:** Recombinant Human C1 Inhibitor

## Key facts

- **NCT ID:** NCT00851409
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-03
- **Final completion:** 2010-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00851409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00851409, "A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00851409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*